Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

494

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 10773 placebo

BI 10773 placebo

DRUG

BI 10773 low dose

BI 10773 low dose

DRUG

BI 10773 high dose

BI 10773 high dose

DRUG

BI 10773 placebo

BI 10773 placebo

Trial Locations (99)

Unknown

1245.33.01014 Boehringer Ingelheim Investigational Site, Birmingham

1245.33.01047 Boehringer Ingelheim Investigational Site, Phoenix

1245.33.01060 Boehringer Ingelheim Investigational Site, Fresno

1245.33.01013 Boehringer Ingelheim Investigational Site, Los Angeles

1245.33.01008 Boehringer Ingelheim Investigational Site, Los Gatos

1245.33.01019 Boehringer Ingelheim Investigational Site, National City

1245.33.01055 Boehringer Ingelheim Investigational Site, Paramount

1245.33.01012 Boehringer Ingelheim Investigational Site, Santa Ana

1245.33.01054 Boehringer Ingelheim Investigational Site, Denver

1245.33.01046 Boehringer Ingelheim Investigational Site, Bradednton

1245.33.01050 Boehringer Ingelheim Investigational Site, Brooksville

1245.33.01059 Boehringer Ingelheim Investigational Site, Chiefland

1245.33.01028 Boehringer Ingelheim Investigational Site, Clearwater

1245.33.01029 Boehringer Ingelheim Investigational Site, Fleming Island

1245.33.01048 Boehringer Ingelheim Investigational Site, Hollywood

1245.33.01033 Boehringer Ingelheim Investigational Site, New Port Richey

1245.33.01027 Boehringer Ingelheim Investigational Site, Atlanta

1245.33.01040 Boehringer Ingelheim Investigational Site, Decatur

1245.33.01062 Boehringer Ingelheim Investigational Site, Lawrenceville

1245.33.01020 Boehringer Ingelheim Investigational Site, Chicago

1245.33.01044 Boehringer Ingelheim Investigational Site, Chicago

1245.33.01024 Boehringer Ingelheim Investigational Site, Des Moines

1245.33.01022 Boehringer Ingelheim Investigational Site, Saint Louis

1245.33.01056 Boehringer Ingelheim Investigational Site, Olive Branch

1245.33.01032 Boehringer Ingelheim Investigational Site, Kansas City

1245.33.01017 Boehringer Ingelheim Investigational Site, Omaha

1245.33.01043 Boehringer Ingelheim Investigational Site, Las Vegas

1245.33.01051 Boehringer Ingelheim Investigational Site, New Hartford

1245.33.01007 Boehringer Ingelheim Investigational Site, Greensboro

1245.33.01003 Boehringer Ingelheim Investigational Site, Jacksonville

1245.33.01016 Boehringer Ingelheim Investigational Site, Salisbury

1245.33.01005 Boehringer Ingelheim Investigational Site, Statesville

1245.33.01038 Boehringer Ingelheim Investigational Site, Wilmington

1245.33.01026 Boehringer Ingelheim Investigational Site, Winston-Salem

1245.33.01025 Boehringer Ingelheim Investigational Site, Cincinnati

1245.33.01001 Boehringer Ingelheim Investigational Site, Columbus

1245.33.01031 Boehringer Ingelheim Investigational Site, Tulsa

1245.33.01045 Boehringer Ingelheim Investigational Site, Eugene

1245.33.01018 Boehringer Ingelheim Investigational Site, Altoona

1245.33.01041 Boehringer Ingelheim Investigational Site, Carlisle

1245.33.01042 Boehringer Ingelheim Investigational Site, Landsdale

1245.33.01004 Boehringer Ingelheim Investigational Site, Greer

1245.33.01036 Boehringer Ingelheim Investigational Site, Mt. Pleasant

1245.33.01035 Boehringer Ingelheim Investigational Site, Seneca

1245.33.01058 Boehringer Ingelheim Investigational Site, Kingsport

1245.33.01037 Boehringer Ingelheim Investigational Site, Memphis

1245.33.01023 Boehringer Ingelheim Investigational Site, Dallas

1245.33.01030 Boehringer Ingelheim Investigational Site, Dallas

1245.33.01006 Boehringer Ingelheim Investigational Site, Houston

1245.33.01011 Boehringer Ingelheim Investigational Site, Houston

1245.33.01002 Boehringer Ingelheim Investigational Site, Sugar Land

1245.33.01049 Boehringer Ingelheim Investigational Site, Salt Lake City

1245.33.01015 Boehringer Ingelheim Investigational Site, Norfolk

1245.33.01009 Boehringer Ingelheim Investigational Site, Richmond

1245.33.01010 Boehringer Ingelheim Investigational Site, Federal Way

1245.33.01061 Boehringer Ingelheim Investigational Site, Milwaukee

1245.33.45006 Boehringer Ingelheim Investigational Site, Aalborg

1245.33.45001 Boehringer Ingelheim Investigational Site, Aarhus C

1245.33.45011 Boehringer Ingelheim Investigational Site, Aarhus C

1245.33.45013 Boehringer Ingelheim Investigational Site, Aarhus C

1245.33.45004 Boehringer Ingelheim Investigational Site, Gentofte Municipality

1245.33.45008 Boehringer Ingelheim Investigational Site, Hillerød

1245.33.45002 Boehringer Ingelheim Investigational Site, Hvidovre

1245.33.45003 Boehringer Ingelheim Investigational Site, København NV

1245.33.3301A Boehringer Ingelheim Investigational Site, Bondy

1245.33.3302A Boehringer Ingelheim Investigational Site, Corbeil-Essonnes

1245.33.3305A Boehringer Ingelheim Investigational Site, La Rochelle

1245.33.3306A Boehringer Ingelheim Investigational Site, Marseille

1245.33.3308A Boehringer Ingelheim Investigational Site, Montbrison

1245.33.3309A Boehringer Ingelheim Investigational Site, Nanterre

1245.33.3310A Boehringer Ingelheim Investigational Site, Nantes

1245.33.3304A Boehringer Ingelheim Investigational Site, Narbonne

1245.33.3303A Boehringer Ingelheim Investigational Site, Saint-Mandé

1245.33.35302 Boehringer Ingelheim Investigational Site, Dublin

1245.33.35303 Boehringer Ingelheim Investigational Site, Dublin

1245.33.35304 Boehringer Ingelheim Investigational Site, Dublin

1245.33.35104 Boehringer Ingelheim Investigational Site, Aveiro

1245.33.35101 Boehringer Ingelheim Investigational Site, Coimbra

1245.33.35102 Boehringer Ingelheim Investigational Site, Lisbon

1245.33.35106 Boehringer Ingelheim Investigational Site, Lisbon

1245.33.35107 Boehringer Ingelheim Investigational Site, Lisbon

1245.33.82008 Boehringer Ingelheim Investigational Site, Daejeon

1245.33.82007 Boehringer Ingelheim Investigational Site, Gwangju

1245.33.82001 Boehringer Ingelheim Investigational Site, Seoul

1245.33.82003 Boehringer Ingelheim Investigational Site, Seoul

1245.33.82004 Boehringer Ingelheim Investigational Site, Seoul

1245.33.82005 Boehringer Ingelheim Investigational Site, Seoul

1245.33.82006 Boehringer Ingelheim Investigational Site, Wŏnju

1245.33.82002 Boehringer Ingelheim Investigational Site, Yangsan

1245.33.44001 Boehringer Ingelheim Investigational Site, Bath

1245.33.44003 Boehringer Ingelheim Investigational Site, Birmingham

1245.33.44006 Boehringer Ingelheim Investigational Site, Blackburn

1245.33.44005 Boehringer Ingelheim Investigational Site, Dorking

1245.33.44009 Boehringer Ingelheim Investigational Site, Headington

1245.33.44008 Boehringer Ingelheim Investigational Site, Leicester

1245.33.44004 Boehringer Ingelheim Investigational Site, Liverpool

1245.33.44007 Boehringer Ingelheim Investigational Site, Wembley

1245.33.44002 Boehringer Ingelheim Investigational Site, Whitstable

1245.33.44010 Boehringer Ingelheim Investigational Site, Wymondham

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01011868 - Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter